|Articles|November 25, 2014
- Immunotherapy (Issue 4)
- Volume 4
- Issue 1
Potential Immunotherapies for Head and Neck Cancers
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
Advertisement
Barbara Burtness, MD, Clinical Research Program Leader, Head and Neck Cancers Program,Co-Director, Developmental Therapeutics Research Program,Professor of Medicine (Medical Oncology), Yale Cancer Center, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
<<<
Articles in this issue
over 11 years ago
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Questionover 11 years ago
Programs Prepare for Immuno-Oncology in Clinical Settingover 11 years ago
Right Patient for Immunotherapy in NSCLC Exploredover 11 years ago
Weight May Affect Toxicity of Immunotherapiesover 11 years ago
Adverse Events Associated With Immunotherapy in Lung Cancerover 11 years ago
Immunotherapy Potential Option in Mesothelioma Treatmentover 11 years ago
Immunotherapies for Prostate CancerAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5